Skip to main content
Top
Published in: Surgery Today 1/2014

01-01-2014 | Case report

A giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case

Authors: Masaki Sunagawa, Masatoshi Isogai, Tohru Harada, Yuji Kaneoka, Keitaro Kamei, Atsuyuki Maeda, Yuichi Takayama

Published in: Surgery Today | Issue 1/2014

Login to get access

Abstract

A 46-year-old female underwent total gastrectomy with a combined resection of the pancreatic tail, spleen, and lateral segment of the liver surgery after conservative medical management for a perforated advanced gastric cancer. The histological findings showed poorly differentiated adenocarcinoma, and the tumor was Stage IIIC. S-1 and “Kampo-Juzen-taiho-to” were administered as postoperative adjuvant chemo-immunotherapy. A Krukenberg tumor was identified 4 years later. The histological findings strongly suggested the presence of peritoneal dissemination, and S-1-based combined chemotherapies using key drugs such as CDDP, CPT-11, and taxane with the biochemical response modifier “Lentinan” was administered. However, the Krukenberg tumor rapidly increased in size after 4 years and she complained of abdominal distension. Therefore, it was removed with neither difficulties nor apparent recurrent disease, which was thought to be due to the S-1-based combined chemotherapy and the immunological agents are likely to have contributed to her long survival and good quality of life.
Literature
1.
go back to reference Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol. 2004;87:39–45.PubMedCrossRef Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol. 2004;87:39–45.PubMedCrossRef
2.
go back to reference Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.PubMedCrossRef Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.PubMedCrossRef
3.
go back to reference Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef
4.
go back to reference Okuyama T, Korenaga D, Koushi K, Itoh S, Kawanaka H, Ikeda Y, et al. The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience. Surg Today. 2011;41:935–40.PubMedCrossRef Okuyama T, Korenaga D, Koushi K, Itoh S, Kawanaka H, Ikeda Y, et al. The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience. Surg Today. 2011;41:935–40.PubMedCrossRef
5.
go back to reference Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K, Kanagawa Lentinan Research Group. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology. 1999;46:2662–8.PubMed Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K, Kanagawa Lentinan Research Group. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology. 1999;46:2662–8.PubMed
6.
go back to reference Horie Y, Kato K, Kameoka S, Hamano K. Bu ji (hozai) for treatment of postoperative gastric cancer patients. Am J Chin Med. 1994;22:309–19.PubMedCrossRef Horie Y, Kato K, Kameoka S, Hamano K. Bu ji (hozai) for treatment of postoperative gastric cancer patients. Am J Chin Med. 1994;22:309–19.PubMedCrossRef
7.
go back to reference Israel SL, Helsel EV Jr, Hausman DH. The challenge of metastatic ovarian carcinoma. Am J Obstet Gynecol. 1965;93:1094–101.PubMed Israel SL, Helsel EV Jr, Hausman DH. The challenge of metastatic ovarian carcinoma. Am J Obstet Gynecol. 1965;93:1094–101.PubMed
8.
go back to reference Jiang R, Tang J, Cheng X, Zang RY. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol. 2009;35:92–7.PubMedCrossRef Jiang R, Tang J, Cheng X, Zang RY. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol. 2009;35:92–7.PubMedCrossRef
9.
go back to reference Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93:87–91.PubMedCrossRef Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93:87–91.PubMedCrossRef
10.
go back to reference Chang TC, Changchien CC, Tseng CW, Lai CH, Tseng CJ, Lin SE, et al. Retrograde lymphatic spread: a likely route for metastatic ovarian cancers of gastrointestinal origin. Gynecol Oncol. 1997;66:372–7.PubMedCrossRef Chang TC, Changchien CC, Tseng CW, Lai CH, Tseng CJ, Lin SE, et al. Retrograde lymphatic spread: a likely route for metastatic ovarian cancers of gastrointestinal origin. Gynecol Oncol. 1997;66:372–7.PubMedCrossRef
11.
go back to reference Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54–9.PubMedCrossRef Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54–9.PubMedCrossRef
12.
go back to reference Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T, et al. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol. 2011;2:339–43.PubMedCentralPubMedCrossRef Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T, et al. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol. 2011;2:339–43.PubMedCentralPubMedCrossRef
Metadata
Title
A giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case
Authors
Masaki Sunagawa
Masatoshi Isogai
Tohru Harada
Yuji Kaneoka
Keitaro Kamei
Atsuyuki Maeda
Yuichi Takayama
Publication date
01-01-2014
Publisher
Springer Japan
Published in
Surgery Today / Issue 1/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0339-x

Other articles of this Issue 1/2014

Surgery Today 1/2014 Go to the issue